Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from NICE technology appraisal guidance · Last verified 3 Oct 2026 · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

What NICE decided

Appraisals by recommendation type

Recommended or optimised

836

Cancer Drugs Fund or Innovative Medicines Fund

Only in research

Not recommended

145

Terminated (no company submission)

177

Recommended: the NHS in England should fund it for the use it is licensed for.
Optimised: recommended, but for a narrower group of patients than the licence covers.
Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
Only in research: to be used only as part of a study.
Not recommended: NICE decided the NHS should not fund it for this use.
Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

Terminated (no company submission)

177 appraisals, newest first, page 2 of 2

Appraisal	Medicine page	NICE recommendation	Published	Status
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) NICE TA730	Avapritinib	Terminated (no company submission)	29 Sep 2021	Current
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA727	Isatuximab	Terminated (no company submission)	22 Sep 2021	Current
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA726	Daratumumab	Terminated (no company submission)	22 Sep 2021	Current
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) NICE TA717	Duvelisib	Terminated (no company submission)	21 Jul 2021	Current
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) NICE TA714	Dasatinib	Terminated (no company submission)	14 Jul 2021	Current
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) NICE TA703	Ibrutinib	Terminated (no company submission)	26 May 2021	Current
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) NICE TA702	Ibrutinib	Terminated (no company submission)	26 May 2021	Current
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) NICE TA701	—	Terminated (no company submission)	19 May 2021	Current
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) NICE TA700	Selinexor	Terminated (no company submission)	19 May 2021	Replaced by TA970
Teduglutide for treating short bowel syndrome (terminated appraisal) NICE TA690	Teduglutide	Terminated (no company submission)	21 Apr 2021	Current
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) NICE TA686	Blinatumomab	Terminated (no company submission)	31 Mar 2021	Current
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) NICE TA678	Omalizumab	Terminated (no company submission)	24 Feb 2021	Current
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) NICE TA675	—	Terminated (no company submission)	17 Feb 2021	Current
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) NICE TA674	Pembrolizumab	Terminated (no company submission)	17 Feb 2021	Current
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) NICE TA662	Durvalumab	Terminated (no company submission)	25 Nov 2020	Current
Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) NICE TA652	Alpelisib	Terminated (no company submission)	7 Oct 2020	Replaced by TA816
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) NICE TA648	Dupilumab	Terminated (no company submission)	9 Sep 2020	Current
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) NICE TA647	Eculizumab	Terminated (no company submission)	2 Sep 2020	Current
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) NICE TA646	—	Terminated (no company submission)	2 Sep 2020	Current
Ranibizumab for treating diabetic retinopathy (terminated appraisal) NICE TA637	—	Terminated (no company submission)	30 Jun 2020	Current
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) NICE TA636	Eculizumab	Terminated (no company submission)	30 Jun 2020	Current
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) NICE TA635	Ramucirumab	Terminated (no company submission)	30 Jun 2020	Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) NICE TA634	Daratumumab	Terminated (no company submission)	30 Jun 2020	Current
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) NICE TA625	—	Terminated (no company submission)	4 Mar 2020	Current
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) NICE TA618	Atezolizumab	Terminated (no company submission)	15 Jan 2020	Current
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) NICE TA609	Ramucirumab	Terminated (no company submission)	30 Oct 2019	Current
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) NICE TA608	Ibrutinib	Terminated (no company submission)	30 Oct 2019	Current
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) NICE TA603	Lenalidomide	Terminated (no company submission)	25 Sep 2019	Current
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA602	Pomalidomide	Terminated (no company submission)	25 Sep 2019	Current
Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) NICE TA601	—	Terminated (no company submission)	25 Sep 2019	Current
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) NICE TA594	Brentuximab Vedotin	Terminated (no company submission)	14 Aug 2019	Replaced by TA1059
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) NICE TA582	Cabozantinib	Terminated (no company submission)	24 May 2019	Replaced by TA849
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) NICE TA576	Bosutinib	Terminated (no company submission)	17 Apr 2019	Current
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) NICE TA570	Pembrolizumab	Terminated (no company submission)	20 Mar 2019	Current
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) NICE TA568	Abatacept	Terminated (no company submission)	13 Mar 2019	Current
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) NICE TA564	Dabrafenib	Terminated (no company submission)	27 Feb 2019	Replaced by TA898
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) NICE TA560	Bevacizumab	Terminated (no company submission)	20 Feb 2019	Current
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) NICE TA549	Denosumab	Terminated (no company submission)	5 Dec 2018	Current
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) NICE TA548	Decitabine	Terminated (no company submission)	5 Dec 2018	Current
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) NICE TA470	Ofatumumab	Terminated (no company submission)	23 Aug 2017	Current
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) NICE TA469	Idelalisib	Terminated (no company submission)	23 Aug 2017	Current
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) NICE TA468	—	Terminated (no company submission)	23 Aug 2017	Current
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) NICE TA454	Daratumumab	Terminated (no company submission)	5 Jul 2017	Current
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) NICE TA453	Bortezomib	Terminated (no company submission)	5 Jul 2017	Current
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) NICE TA452	Ibrutinib	Terminated (no company submission)	5 Jul 2017	Current
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) NICE TA444	Afatinib	Terminated (no company submission)	24 May 2017	Current
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) NICE TA438	Alectinib	Terminated (no company submission)	29 Mar 2017	Current
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) NICE TA437	Ibrutinib	Terminated (no company submission)	22 Mar 2017	Current
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) NICE TA436	Bevacizumab	Terminated (no company submission)	22 Mar 2017	Current
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) NICE TA435	Tenofovir Alafenamide	Terminated (no company submission)	22 Mar 2017	Current
Elotuzumab for previously treated multiple myeloma (terminated appraisal) NICE TA434	Elotuzumab	Terminated (no company submission)	22 Mar 2017	Current
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) NICE TA382	Eltrombopag	Terminated (no company submission)	27 Jan 2016	Current
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) NICE TA362	—	Terminated (no company submission)	28 Oct 2015	Current
Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) NICE TA361	—	Terminated (no company submission)	28 Oct 2015	Current
Ruxolitinib for treating polycythaemia vera (terminated appraisal) NICE TA356	Ruxolitinib	Terminated (no company submission)	23 Sep 2015	Current
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) NICE TA353	Bevacizumab	Terminated (no company submission)	26 Aug 2015	Current
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) NICE TA351	Cangrelor	Terminated (no company submission)	22 Jul 2015	Current
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) NICE TA334	Regorafenib	Terminated (no company submission)	25 Feb 2015	Current
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) NICE TA328	Idelalisib	Terminated (no company submission)	17 Dec 2014	Replaced by TA604
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) NICE TA302	—	Terminated (no company submission)	27 Nov 2013	Current
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) NICE TA286	—	Terminated (no company submission)	22 May 2013	Current
Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) NICE TA281	—	Terminated (no company submission)	24 Apr 2013	Current
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) NICE TA277	—	Terminated (no company submission)	27 Mar 2013	Current
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) NICE TA273	Tadalafil	Terminated (no company submission)	23 Jan 2013	Current
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) NICE TA270	Decitabine	Terminated (no company submission)	12 Dec 2012	Current
Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) NICE TA262	Adalimumab	Terminated (no company submission)	25 Jul 2012	Replaced by TA329
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) NICE TA240	Panitumumab	Terminated (no company submission)	14 Dec 2011	Current
Agomelatine for the treatment of major depressive episodes (terminated appraisal) NICE TA231	—	Terminated (no company submission)	27 Jul 2011	Current
Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) NICE TA224	Golimumab	Terminated (no company submission)	22 Jun 2011	Replaced by TA375
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) NICE TA207	Temsirolimus	Terminated (no company submission)	27 Oct 2010	Current
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) NICE TA206	Bendamustine	Terminated (no company submission)	27 Oct 2010	Current
Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) NICE TA194	Denosumab	Terminated (no company submission)	28 Jul 2010	Current
Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) NICE TA175	Gefitinib	Terminated (no company submission)	22 Jul 2009	Current
Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy NICE TA150	Cetuximab	Terminated (no company submission)	25 Jun 2008	Current
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) NICE TA149	—	Terminated (no company submission)	25 Jun 2008	Current
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) NICE TA148	Bevacizumab	Terminated (no company submission)	25 Jun 2008	Current
Bevacizumab for the first-line treatment of metastatic breast cancer NICE TA147	Bevacizumab	Terminated (no company submission)	25 Jun 2008	Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

NICE technology appraisal guidance ↗ appraisal titles, dates and status, from each appraisal page
NICE technology appraisal recommendations data ↗ NICE's categorisation of every recommendation

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

NICE technology appraisals

What NICE decided

Terminated (no company submission)

How this page is built